Mark E Dudley

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
    M E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 24:363-73. 2001
  2. ncbi Adoptive cell transfer therapy
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Semin Oncol 34:524-31. 2007
  3. ncbi Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
  4. ncbi Adoptive-cell-transfer therapy for the treatment of patients with cancer
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B 34, 10 Center Drive, Bethesda, Maryland 20892 1502, USA
    Nat Rev Cancer 3:666-75. 2003
  5. ncbi Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:332-42. 2003
  6. ncbi To bead or not to bead
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 26:187-9. 2003
  7. ncbi A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:243-51. 2002
  8. ncbi Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
  9. ncbi Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
    Marybeth S Hughes
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 16:457-72. 2005
  10. ncbi Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006

Detail Information

Publications65

  1. ncbi Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
    M E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 24:363-73. 2001
    ..The lack of clinical effectiveness of this protocol suggests that transfer of different or additional cell types or that modulation of the recipient host environment is required for successful therapy...
  2. ncbi Adoptive cell transfer therapy
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Semin Oncol 34:524-31. 2007
    ....
  3. ncbi Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    ..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens...
  4. ncbi Adoptive-cell-transfer therapy for the treatment of patients with cancer
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B 34, 10 Center Drive, Bethesda, Maryland 20892 1502, USA
    Nat Rev Cancer 3:666-75. 2003
    ..These studies provide a blueprint for the wider application of adoptive-cell-transfer therapy, and emphasize the requirement for in vivo persistence of the cells for therapeutic efficacy...
  5. ncbi Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:332-42. 2003
    ..These methods were efficient at generating TILs suitable for adoptive transfer therapy...
  6. ncbi To bead or not to bead
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 26:187-9. 2003
    ..These results lay a solid foundation for the clinical application of bead-based T cell activation, and promote efforts to develop the therapeutic strategy of in vivo immunization, ex vivo T cell activation, and adoptive cell transfer...
  7. ncbi A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:243-51. 2002
    ..This study established a nonmyeloablative-conditioning regimen that could be safely administered in conjunction with adoptive T-cell transfer and IL-2 in patients with metastatic melanoma...
  8. ncbi Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
    ....
  9. ncbi Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
    Marybeth S Hughes
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 16:457-72. 2005
    ..TCR-transduced T-cells are thus attractive candidates for evaluation in cell transfer therapies of patients with cancer...
  10. ncbi Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  11. ncbi Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  12. ncbi Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
    ..This trial was registered at www.ClinicalTrials.gov as NCI-07-C-0174 and NCI-07-C-0175...
  13. ncbi Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:6527-39. 2006
    ..These studies demonstrate the feasibility and safety of using vaccine-induced PBMC for cell transfer, but suggests that they are not as effective as TIL in adoptive immunotherapy even when transferred into lymphodepleted hosts...
  14. ncbi Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2
    Bianca Heemskerk
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 19:496-510. 2008
    ..In this study, insertion of the IL-2 gene into antitumor TILs increased their ability to survive after IL-2 withdrawal in vitro but did not increase their in vivo persistence or clinical effectiveness...
  15. ncbi A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 33:648-58. 2010
    ..The methodology described here could be readily applied for engineering CD8+ T cells with antitumor specificity for human adoptive immunotherapy...
  16. ncbi Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, CRC 3-3940, 10 Center Dr MSC 1201, Bethesda MD 20892-1202, USA
    J Clin Oncol 23:2346-57. 2005
    ..CONCLUSION: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma...
  17. ncbi High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 171:3287-95. 2003
    ..These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma...
  18. ncbi Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother (1997) 28:53-62. 2005
    ....
  19. ncbi Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    ....
  20. ncbi Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:4550-7. 2011
    ..We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma...
  21. ncbi Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
    Khoi Q Tran
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 31:742-51. 2008
    ....
  22. ncbi Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
    Laura A Johnson
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:6548-59. 2006
    ..We propose that inducing expression of this highly avid TCR in patient PBMC has the potential to induce tumor regression, as an "off-the-shelf" reagent for allogeneic melanoma patient gene therapy...
  23. ncbi Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7125-30. 2004
    ....
  24. ncbi Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 18:843-51. 2010
    ..We speculate that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells...
  25. ncbi Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy
    Peter A Prieto
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:547-56. 2010
    ..Thus, optimized CD8(+) selection combines the benefits of antigen-selected TIL and young TIL for generating lymphocyte cultures for ACT, and should be evaluated in cell transfer therapy protocols...
  26. ncbi B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
    ....
  27. ncbi Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma
    Franz O Smith
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1201, USA
    J Immunother 32:870-4. 2009
    ..Cell proliferation in vitro was further stimulated by additional vaccine and interleukin-2. The patient has an ongoing partial response at 10 months after the last treatment...
  28. ncbi Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Blood 114:1537-44. 2009
    ..These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses...
  29. ncbi Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7622-9. 2004
    ..A similar analysis may also be useful for monitoring autoimmune responses...
  30. ncbi Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells
    Marc R Theoret
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    Hum Gene Ther 19:1219-32. 2008
    ..These studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients...
  31. ncbi Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    J Immunother (1997) 28:258-67. 2005
    ....
  32. ncbi Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement
    Kevin M Friedman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda 20892 1201, MD, USA
    J Immunother 34:651-61. 2011
    ..These data demonstrate that the addition of ECCE to TIL production will enable the treatment of patients that are ineligible using current methods...
  33. ncbi Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma
    Steven Yeh
    National Eye Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Ophthalmology 116:981-989.e1. 2009
    ..To describe the ophthalmic and systemic autoimmune findings after successful adoptive cell transfer of ex vivo expanded, autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) for metastatic melanoma...
  34. ncbi Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA
    Blood 105:241-50. 2005
    ....
  35. ncbi Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor
    Robert P T Somerville
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 10:69. 2012
    ..To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE®, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes...
  36. ncbi Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL
    Stephanie L Goff
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:840-7. 2010
    ..As more centers begin exploring the use of adoptive transfer with TIL, this compendium may provide a framework for therapeutic decision making and future investigation...
  37. ncbi CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma
    Mark E Dudley
    Surgery Branch and Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 16:6122-31. 2010
    ..However, the generation of a unique tumor-reactive TIL culture for each patient may be prohibitively difficult. We therefore investigated the clinical and immunologic impact of unscreened, CD8+ enriched "young" TIL...
  38. ncbi The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans
    Anran Wang
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20817, USA
    Sci Transl Med 4:149ra120. 2012
    ..These findings demonstrate the favorable engraftment fitness for human T(CM)-derived clones, but further efforts to improve their antitumor efficacy are still necessary...
  39. ncbi Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma
    Melissa M Alvarez-Downing
    Surgery Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 Hatfield CRC, Room 3 5930, Bethesda, MD 20892 1201, USA
    World J Surg Oncol 10:113. 2012
    ..To increase the availability of this promising therapy in patients with advanced melanoma, a minimally invasive approach to procure tumor for TIL generation is warranted...
  40. ncbi Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy
    R Taylor Ripley
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Ann Surg Oncol 17:163-70. 2010
    ..Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy...
  41. ncbi Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience
    Jacob A Klapper
    Tumor Immunology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Thorac Cardiovasc Surg 140:1276-82. 2010
    ..This study was undertaken to examine outcomes of patients with melanoma undergoing thoracic metastasectomy in preparation for investigational immunotherapy...
  42. ncbi T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:620-6. 2011
    ..It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy...
  43. ncbi Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
    Richard A Morgan
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 36:133-51. 2013
    ....
  44. ncbi Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, NIH Clinical Center, 10 Center Drive, Bethesda, MD 20892-1502, USA
    Cancer Immunol Immunother 53:817-24. 2004
    ..Since the final antigenic nonamer is not directly produced by the proteasome, additional further factors may influence the antigenic peptide availability, such as post-proteasomal processing and intracellular peptide transport...
  45. ncbi Adoptive cell therapy: genetic modification to redirect effector cell specificity
    Richard A Morgan
    Surgery Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer J 16:336-41. 2010
    ..Initial clinical trial results have demonstrated that both T-cell receptor- and chimeric antigen receptor-engineered T cells can be administered to cancer patients and mediate tumor regression...
  46. ncbi Adoptive cell therapy for the treatment of patients with metastatic melanoma
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA
    Curr Opin Immunol 21:233-40. 2009
    ..We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers...
  47. ncbi Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma
    Alena Gros
    National Cancer Institute, Bethesda, MD, USA
    Clin Cancer Res 18:5212-23. 2012
    ..Myeloid-derived suppressor cells (MDSC) have emerged as an immune-regulatory cell type that is expanded in tumor-bearing mice, but less is known about their immune-suppressive role in patients with cancer...
  48. ncbi Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
    Xin Yao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 119:5688-96. 2012
    ..All 5 clinical trials are registered at www.clinicaltrials.gov as NCT00001832, NCT00096382, NCT00335127, NCT00509496, and NCT00513604...
  49. ncbi Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes
    Kevin M Friedman
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Immunother 35:400-8. 2012
    ..These results demonstrate that at least 20% of metastatic melanomas contain CD4+ lymphocytes with specific tumor recognition and suggest a possible role for CD4+ cells in the effectiveness of adoptive cell therapy...
  50. ncbi Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 8:299-308. 2008
    ....
  51. ncbi T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:6057-64. 2004
    ....
  52. ncbi Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy
    Jacob A Klapper
    Surgery Branch National Cancer Institute, CRC 3 5752 10 Center Drive, Bethesda, MD 20892 1201, USA
    J Immunol Methods 345:90-9. 2009
    ..This bioreactor may simplify the process of the rapid expansion of TIL under stringent regulatory conditions thereby enabling other institutions to pursue this form of ACT...
  53. ncbi Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010
    ..Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326...
  54. ncbi Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Proc Natl Acad Sci U S A 101:14639-45. 2004
    ..These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes...
  55. ncbi Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application
    Ling Zhang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 35:430-9. 2012
    ..These results support the clinical application of adoptive transfer of young TIL engineered with the NFAT.hIL12 vector as a new approach for cancer immunotherapy...
  56. ncbi Functional heterogeneity of vaccine-induced CD8(+) T cells
    Vladia Monsurro
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:5933-42. 2002
    ..In addition, CD45RA/CD27 expression may be more informative about the status of activation of circulating T cells than their status of differentiation...
  57. ncbi Successful treatment of melanoma brain metastases with adoptive cell therapy
    Jenny J Hong
    National Cancer Institute, Surgery Branch and The Clinical Center of the NIH, Radiology and Imaging Sciences, Bethesda, Maryland, USA
    Clin Cancer Res 16:4892-8. 2010
    ..The response rate and duration of melanoma brain metastases, as well as the overall response rate, response duration, and survival for these patients, are presented...
  58. ncbi New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
    ..In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies...
  59. ncbi Adoptive immunotherapy for cancer: harnessing the T cell response
    Nicholas P Restifo
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 12:269-81. 2012
    ..We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication...
  60. ncbi Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
    Maria R Parkhurst
    NIH, National Cancer Institute, Surgery Branch, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6287-97. 2011
    ..Therefore, we initiated in a clinical trial to evaluate the efficacy of adoptively transferred autologous NK cells to treat patients with cancers who were ineligible for treatment with TIL...
  61. ncbi IRF5 gene polymorphisms in melanoma
    Lorenzo Uccellini
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 10:170. 2012
    ....
  62. ncbi Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment
    Jianjian Jin
    Cell Processing Section, Department of Transfusion Medicine, Clinical Center, ational Institutes of Health, Bethesda, MD, USA
    J Immunother 35:283-92. 2012
    ..TIL culture in G-Rex flasks will facilitate the production of TIL at the numbers required for patient treatment at most cell processing laboratories...
  63. ncbi A T-cell receptor associated with naturally occurring human tumor immunity
    Bianca D Santomasso
    Howard Hughes Medical Institute, Laboratory of Molecular Neuro Oncology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19073-8. 2007
    ..Cloned cdr2-specific TCR genes provide a clinically relevant means for immunologic targeting of human gynecologic cancers...
  64. ncbi Cancer immunotherapy
    Steven A Rosenberg
    N Engl J Med 359:1072. 2008
  65. ncbi A stimulating presentation
    Mark E Dudley
    Nat Biotechnol 20:125-6. 2002